PRECIGEN, INC. cotiza a 7.81 USD y tiene una capitalización bursátil de $2.8B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $0.05 | $-0.02 | $-0.01 |
| Estimado | $0.03 | $-0.01 | $-0.04 | $-0.08 |
| Sorpresa | — | +600.0% | +50.0% | +87.5% |
| Métrica | PGEN | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -1141.1% | -38.6% | -1102.5% |
| Net Margin | -2588.2% | -33.6% | -2554.7% |
| FCF Margin | -927.6% | -13.9% | -913.7% |
| ROE | -1198.6% | -40.4% | -1158.2% |
| ROA | -161.2% | -32.0% | -129.2% |
| Current Ratio | 3.09 | 2.84 | +0.25 |
| Debt / Equity | 4.46 | 0.28 | +4.18 |